BIP
BIOL

Brandes Investment Partners’s Biolase, Inc. BIOL Stock Holding History

Brandes Investment Partners’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$27K – 207
2016
Q2 		$27K Buy
+2
New +$31.6K ﹤0.01% 188

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return

Brandes Investment Partners's BIOL Position: Q3 2016 in Review

Brandes Investment Partners sold out of Biolase, Inc. (BIOL) in Q3 2016, closing a stake of 2 shares — an estimated $27K sold.

Brandes Investment Partners first reported a position in BIOL in Q2 2016 and held it in 1 quarter. The position peaked at $27K in Q2 2016. 31 funds tracked by Wall St. Rank hold BIOL as of Q3 2016.

  • Brandes Investment Partners reported no remaining Biolase, Inc. position as of Q3 2016 after selling out during the quarter.
  • Brandes Investment Partners sold 2 Biolase, Inc. shares in Q3 2016, an estimated $27K.
  • Brandes Investment Partners first reported a position in Biolase, Inc. in Q2 2016 and held it in 1 quarter.
  • Brandes Investment Partners's Biolase, Inc. position peaked at $27K in Q2 2016.
  • 31 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2016.

Based on Brandes Investment Partners's 13F filing for Q3 2016, filed 10 Nov 2016.